Lilly is collaborating with the Carlos Slim Foundation and the Mexican Society for Public Health on a five-year effort to improve outcomes for pregnant women with gestational diabetes and their babies. Through the collaboration, we are working to find a less expensive and better way to perform an oral glucose tolerance test to screen for gestational diabetes and help women who test positive avoid complications throughout their pregnancy. The partnership has delivered several important outcomes, including documenting the prevalence of gestational diabetes in Mexico (14%) for the first time at the national level, identifying three subtypes of the disease, and developing a simpler version of the oral glucose tolerance test. In 2022, more than 690,000 people benefited from the educational, diagnosis and improved care through this program.